- Conditions
- Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
- Interventions
- ABF-101, Placebo
- Drug
- Lead sponsor
- Aptabio Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 913
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab (Lucentis(R))
- Drug
- Lead sponsor
- Lawrence S. Morse, MD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Age-Related Macular Degeneration
- Interventions
- No interventions are planned
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Macular Edema With Central Retinal Vein Occlusions
- Interventions
- Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Geographic Atrophy
- Interventions
- No intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Campbell, California • Glendale, California + 19 more
- Conditions
- Choroiditis, Iridocyclitis, Iritis, Retinal Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Interventions
- GEM103
- Biological
- Lead sponsor
- Gemini Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 8 more
- Conditions
- Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
- Interventions
- observational study, VOY-101
- Other · Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
- Conditions
- Macular Degeneration
- Interventions
- abicipar pegol, ranibizumab, sham procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- REGN2176-3, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more
- Conditions
- Retinal Vasculitis
- Interventions
- aflibercept 2 mg
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- OTX-TKI/Sham, Aflibercept/Sham
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more
- Conditions
- Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 68,563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Age-related Macular Degeneration
- Interventions
- Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AKST4290, Placebo, Aflibercept
- Drug
- Lead sponsor
- Alkahest, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
- Conditions
- Age Related Macular Degeneration
- Interventions
- Visual Function Tests
- Other
- Lead sponsor
- ORA, Inc.
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Miami, Florida • Portsmouth, New Hampshire
- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Biological
- Lead sponsor
- Xbrane Biopharma AB
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 26
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
- Conditions
- Age-Related Macular Degeneration, Neovascularization, Choroidal
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 73 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Macular Edema, Branch Retinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
- Conditions
- Glaucoma, Macular Disease, Keratoconus
- Interventions
- OCT imaging, the FDA Cleared iVue
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon